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1996.-The present study was performed in seven healthy 
subjects (aged 22-35 years) to investigate 1) whether plasma 
and urinary endothelin-1 (ET-l) are involved in the response 
to postural changes and 2) the relationship between ET-l 
formation and the renin-angiotensin system (RAS). Six hours 
of standing caused a prompt but very short-lasting increase 
in plasma ET-1 concentration (59% after 5 min, 12% after 1 h) 
and a notable and sustained enhancement of urinary ET-l 
excretion (from 0.59 t 0.10 to 1.43 2 0.28 pg/min, or 142%; 
P < 0.001). Plasma renin activity increased by 169% after 1 h 
of standing. A parallel contraction of urinary volume (-62%), 
sodium excretion (-55%), and free water reabsorption (-24%) 
occurred. The return to the supine position after 6 h of 
orthostasis caused a reduction to baseline values of the ET-l 
urinary excretion and urinary volume within 2 h. Inhibition 
of angiotensin-converting enzyme blunted, but did not elimi- 
nate, the orthostasis-induced increase in ET-1 urinary excre- 
tion (lOO%, P < 0.002) and changes in the renal functions. 
The present results indicate that renal ET-l is involved in the 
hemodynamic long-lasting responses to postural changes and 
that its increase is partially controlled by RAS and suggest 
that ET-l might play a role in the regulation of renal function 
in humans. 
posture; water-electrolyte balance; blood volume; natriuresis; 
angiotensin-converting enzyme inhibitors 
ENDOTHELIN-I (ET-l) is a vasoconstrictor peptide synthe- 
sized by endothelial cells (36) and other cell types, 
including those of lung, kidney, gut, and neurons of the 
paraventricular nucleus of the hypothalamus (14, 20, 
26, 36). The ET-l peptide and the mRNA of its pre- 
cursor, preproendothelin-1, are widespread in the endo- 
thelium of the renal vascular bed and in the inner 
medullary collecting ducts (20,23,27,33,37). Immuno- 
cytochemical studies suggest that renal ET-l secretion 
occurs at the vascular endothelium of arcuate arteries, 
veins, glomerular capillaries and arterioles, peritubu- 
lar capillaries, and vasa recta of distal nephron seg- 
ments (34). In addition to the vascular endothelium, 
different nephron segments and especially renal tu- 
bules secrete abundant amounts of ET-l (28). Endothe- 
lial secretion is highly compartmentalized in tubules, 
with the following secretion hierarchy: inner medullary 
collecting ducts > medullary thick ascending limb > 
cortical collecting ducts >> proximal tubule (28). ET-l 
receptors have been located in the renal artery and 
afferent and efferent glomerular arterioles (ETA recep- 
tor), in glomerular endothelium and possibly mesan- 
gium (ETB receptor), and in the inner medullary collect- 
ing ducts (5, 10,16,30). 
In humans the experimental increase or decrease in 
blood volume was associated with changes of both ET-l 
concentration in plasma and ET-l urinary excretion 
(22), suggesting ET-l involvement in the regulation of 
blood volume. The assumption of a standing position is 
associated with important changes in central blood 
volume, sympathetic activity reflex, cardiac dynamics, 
and the tension of the vascular walls of peripheral 
capacity vessels (1). Renal plasma flow and glomerular 
filtration rate (GFR) decrease, leading to a reduction in 
urinary volume and sodium excretion. There is strong 
evidence that changes of water and mineral excretion 
are induced by changes in baroreceptor activity, with 
the participation of hormonal factors including angio- 
tensin (ANG) II, aldosterone, and antidiuretic hormone 
(1). ET-l is provided with important regulatory activi- 
ties of renal function. When infused in animals, a low 
dose of ET-l causes renal vasoconstriction and de- 
creases renal blood flow and GFR (9, 13, 35). These 
effects are associated with reduced sodium excretion (3) 
and activation of renin and aldosterone release (l&21). 
Moreover, ET-l plasma concentration has been re- 
ported to undergo a prompt but short-lasting increase 
during 30-min tilting test (12, 29). Together, these 
results suggest that ET-l may be involved in the 
adaptative responses to postural changes. 
The present study was aimed at investigating whether 
plasma and/or renal ET-l are involved in the response 
to postural changes and the relationship between ET-l 
renal production and the renin-angiotensin system 
(RAS) in the orthostasis-induced changes in renal 
functions. 
METHODS 
Subjects Investigated 
Seven healthy subjects aged 22-35 years (4 males and 3 
females) were studied. Experimental procedures and the 
purposes of the study were explained to the subjects and all 
gave their informed consent. No subject was a smoker, had 
taken any drug for at least 4 wk, or had any positive family 
history of hypertension or diabetes. 
All the subjects were first examined for serum electrolytes, 
fasting plasma glucose, and creatinine clearance, and urinaly- 
sis was performed. No pathological finding was detected, and 
creatinine clearance ranged within commonly accepted nor- 
mal values. 
Experimental Protocol 
All subjects received a diet containing 108 meq/day NaCl 
(normal sodium diet) throughout the study period. All sub- 
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jects abstained from caffeine, alcohol, and smoking during all 
the experimental days. 
The study was divided into two parts: first, the study of the 
changes of ET-1 in relation to postural changes, and second, 
the study of the relationship between ET-l formation and 
RAS. 
Changes ofET-1 in relation to posture. The subjects, after 
overnight fasting and recumbency, remained supine or as- 
sumed orthostasis for different durations. During each experi- 
mental period all the subjects were given hourly fluid replace- 
ment with tap water equal in volume to the sum of blood 
withdrawn, the insensible loss (30 ml/h), and the previous 
hour’s urine output. 
At 8 AM on the first day of the experiment, subjects were 
requested to remain in the supine position for another 12 h 
(until 8 PM). On the second day of the experiment, at 8 AM, 
subjects were requested to assume the orthostatic position 
and to maintain it until 8 PM. During this day all subjects 
were allowed to walk in the hospital setting. While remaining 
in the standing position they consumed a light lunch and 
dinner at 12 noon and 7 PM, respectively. During the third day 
of the experiment, subjects assumed the upright position 
from 8 AM to 2 PM and then returned to bed in the supine 
position until 8 PM. The sequence of these three periods was 
randomized. 
Blood withdrawal was performed at baseline (8 AM) and 
repeated after 5,10,20,40, and 60 min and then every 2 h for 
each experimental day. Plasma samples for the measure- 
ments of plasma renin activity were collected at baseline and 
after 1, 2, 6, and 12 h. Urinary samples for ET-l and 
creatinine determination were taken at baseline (from 8 PM to 
8 AM) and then every hour during each day of the experiment. 
In addition, the clearances of creatinine, lithium, and free 
water, urinary volume, and sodium excretion were assessed 
on two separate days at 8 AM and at 2 PM after 6-h periods in 
the supine and in the standing positions. The day before the 
study all the subjects were administered lithium carbonate 
(500 mg po) at 11 PM. 
ReLationship between ET-l formation and RAS. To investi- 
gate the relationship between ET-1 formation and the activity 
of RAS, the same subjects previously investigated were 
treated with ramipril (5 mg po at 7 AM), an inhibitor of 
angiotensin-converting enzyme (ACE), whose activity was 
reported to last for -24 h after dosing (11). 
ET-l plasma concentration as well as ET-1 urinary excre- 
tion, the clearances of creatinine, lithium, and free water, 
urinary volume, and total sodium excretion were measured 
on two separate days at baseline (8 AM) and after 6 h in the 
supine or in the standing position. 
Sampling and Extraction Procedures 
Sample collection and extraction of ET-1 were performed as 
previously described (22). Briefly, samples of blood (10 ml) for 
ET-1 measurement were withdrawn in polypropylene tubes 
chilled to 0°C containing 0.5 ml of an inhibitory solution (final 
concentrations in blood: 1 mg/ml EDTA, 500 kallikrein inhibi- 
tor units/ml aprotinin; EDTA, Carlo Erba, Milan, Italy; 
Trasylol, Bayer, Germany). The blood specimens were then 
centrifuged at 3,000 g for 10 min at 4°C;. the plasma was 
immediately frozen and stored at -80°C and extraction was 
performed within 2 days. Urine samples were collected, 
immediately frozen, and stored at -80°C. The urine was also 
extracted within 2 days. 
For extraction, plasma (5 ml) was applied to a Sep-Pak 
octadecyl-silane-Cl8 disposable column (Waters, Milford, MA) 
previously activated by consecutive washings with 3 ml of 
100% methanol, 3 ml of 10% methanol, 3 ml of 20% methanol, 
3 ml of 85% methanol, and 4 ml of 10% methanol. The column 
was then washed with 4 ml of 20% methanol, and the 
adsorbed peptide was eluted with 3 ml of 85% methanol. The 
eluates were evaporated until dry in a centrifugal concentra- 
tor (CTGOe, Heto, Birkerod, Denmark) and stored at -80°C 
until the radioimmunoassay (RIA) was performed. 
A 5-ml aliquot of each urine sample was run on a Sep-Pak 
octadecyl-silane-C 18 disposable column previously activated 
with 10 ml of acetonitrile-0.1% trifluoroacetic acid (99.9:O.l 
vol/vol). The column was then washed with 10 ml of water, 
and the adsorbed peptide was eluted with 2 ml of acetonitrile- 
0.1% trifluoroacetic acid (60:40). The elution fraction was 
lyophilized, and the dried residue was stored at -80°C until 
assayed. 
The ET-1 recovery rates, calculated by the addition of 
different concentrations of cold ET-l, were 70 2 9% from 
plasma and 90 t 5% from urine. 
High-Performance Liquid Chromatography of ET-l 
To assess changes in the elution profile of plasma and 
urinary ET-l induced by orthostasis, plasma- and urine- 
extracted samples were chromatographed as previously de- 
scribed (22). Briefly, vacuum-dried plasma (10 ml) and urine 
(10 ml) extra c t s were dissolved in 0.5 ml of 70% mobile phase 
A (0.1% trifluoroacetic acid in water)/30% mobile phase B 
(0.1% trifluoroacetic acid in acetonitrile) and centrifuged at 
1,700 g for 10 min. A 250~ul aliquot of supernatant was then 
injected with a Hamilton syringe (Hamilton, Bonaduz, Swit- 
zerland) in a model U6K injector (Waters, Milford, MA) 
equipped with a 2,000~ul loop and connected to a reverse- 
phase uBondapak C 18 column (3.9 X 300 mm, Waters, 
Milford, MA). The column was previously calibrated with 
pure standard unlabeled ET-1 and 1251-labeled ET-1 (la51- 
ET-l; 1,300 Ci/mmol, Peninsula, Belmont, CA). The purity of 
the 12”I-ET-1 was preliminarily checked by injection into the 
high-performance liquid chromatography (HPLC) system. 
The HPLC equipment consisted of two model 6000A pumps, a 
model 660 solvent programmer (Waters, Milford, MA), and a 
fraction collector (7000 Ultrorac LKB, Bromma, Sweden). The 
chromatography was performed by isocratic elution with 70% 
mobile phase A (0.1% trifluoroacetic acid in water)/30% 
mobile phase B (0.1% trifluoroacetic acid in acetonitrile) from 
0 to 10 min followed by a linear gradient to 40% mobile phase 
A/60% mobile phase B up to 40 min at a flow rate of 1.0 
ml/min. The experiments were performed at room tempera- 
ture. The eluate was collected in 1-min fractions in polypropyl- 
ene tubes. 
The concentrations of 1251-ET-l in the HPLC fractions were 
measured in a gamma counter (Beckman, Fullerton, CA). The 
concentrations of ET-1 were measured by RIA. 
RIA of ET-l 
ET-1 immunoreactivity was measured by a specific RIA for 
ET-l using rabbit polyclonal anti-ET-l serum as previously 
described (22). Briefly, the extracted samples were resus- 
pended in phosphate buffer immediately before the assay was 
performed. The standard ET-l (Peninsula, Belmont, CA) or 
plasma and urine samples (100 ul) were mixed with 100 ul of 
rabbit anti-ET-l serum (Peninsula, Belmont, CA), diluted 
with RIA buffer at a final dilution of 1:24,000 for urine and 
1:72,000 for plasma and HPLC fractions. Antibody cross- 
reactivities were 100% with ET-l (porcine, human), 7% with 
endothelin-2 (human), 7% with endothelin-3 (rat, human), 
35% with Big endothelin (porcine), 17% with Big endothelin 
(human), and 3% with sarafotoxin S6b. There was no cross- 
reactivity with Big endothelin 22-38 (human), alpha-human 
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atria1 natriuretic peptide, brain natriuretic peptide (porcine), 
ANG I, ANG II, ANG III, vasopressin, adrenocorticotropic 
hormone, or vasoactive intestinal peptide. The minimum 
detectable concentration was 0.1 pg/tube. The coefficients of 
intra-assay and interassay variations were 4% (n = 11) and 
10% (n = 11) for plasma and 3% (n = 11) and 12% (n = 11) for 
urine, respectively. Results were expressed as picograms per 
milliliter for plasma and picograms per minute for urine. 
Analytical Methods and Calculations 
Plasma and urine were assayed for electrolytes (PNa, 
plasma sodium; U Na, urinary sodium; PLi, plasma lithium; 
ULi, urinary lithium) by an ion-sensitive electrode (Instrumen- 
tation Beckmann Astra, Beckmann Instruments, Brea, CA) 
and for creatinine by the Jaffe reaction (Instrumentation 
Beckmann Astra). Osmolar clearance (C,,,), lithium clear- 
ance (CL;), and creatinine clearance (C,,) were calculated with 
the use of standard formulas. Free water clearance (C,+> was 
calculated as 
C H 0 2 = (1 - u,,,/p,,,,> x v  
where U,,, (mosmol/kgHzO) and P,,, (mosmol/kgHzO) are 
the simultaneous urinary and plasma osmolalities, respec- 
tively, and V (ml/min) is the simultaneous rate of urinary 
flow. Negative values of CH o> occur when the urine is hyper- 
tonic to the plasma, and, by convention, these negative values 
are referred to as free water reabsorption (Tn20) where 
T H,O = -CH,O 
GFR was estimated by the clearance of endogenous creati- 
nine. Delivery of proximal tubular fluid to the distal nephron, 
i.e., distal delivery filtrate (DDF), was approximated by V 
factored by GFR (4, 27). The relationship between TH o and 
DDF in supine and standing positions was calculated. 2 
Blood samples for plasma renin activity were collected in 
ice-cold tubes and immediately centrifuged. Plasma samples 
were then stored at -20°C. Plasma renin activity was then 
measured by RIA. 
Statistical Analysis 
If  not otherwise indicated, data are presented as means 2 
SD. Comparisons of a single observation between groups were 
made with Student’s t-test. Repeated observations over the 
experimental days were analyzed by analysis of variance for 
repeated measures (ANOVA). The relationship between 
TH dGFR and V/GFR was evaluated by simple regression 
analysis. All statistical analyses were performed with BMDP 
statistical software (BMDP Statistical Software, Los Angeles, 
CA). 
RESULTS 
Changes of ET-l in Relation to Posture 
Plasma concentration and urinary excretion of ET-l 
in the supine position remained steady throughout the 
12-h study period (Tables 1 and 2, Fig. 1). During the 
first 6 h, the mean ET-1 urinary excretion was 0.59 ? 
0.10 pg/min. The parameters of the renal function 
measured after the 6-h supine position are reported in 
Table 3. 
After standing position was assumed, ET-1 concentra- 
tion in plasma significantly increased after 5 min (from 
0.51 t 0.12 at baseline to 0.81 t 0.20 pg/ml, P < 0.05), 
Table 1. Endothelin-1 (ET-l) concentration in plasma 
and percent changes vs. baseline during three 
experimental periods 
Supine Standing Standing-Supine 
Hours 
ET- 1 concn, ET- 1 concn, ET- 1 concn, 
P&l1 %Change pg/ml %Change pg/ml %Change 
8 0.55 + 0.10 0.51+ 0.12 0.50 2 0.10 
9 0.5820.14 5 0.57 + 0.13 12 0.59 + 0.13 18 
10 0.5620.21 2 0.51* 0.18 0 0.59 + 0.12 18 
12 0.58kO.11 5 0.55 + 0.10 8 0.55 + 0.12 10 
14 0.69kO.18 25 0.59 k 0.16 16 0.52 -t 0.24 4 
16 0.5420.13 -2 0.55 + 0.11 8 0.53 -t 0.13 6 
18 0.57kO.19 4 0.52 + 0.15 2 0.52 + 0.15 4 
20 0.59kO.07 7 0.58 ? 0.06 14 0.58 k 0.07 16 
Values are means + SD. 
but the increase was very short-lasting, and the differ- 
ences in comparison with baseline and supine position 
were no longer significant for all the remaining study 
period (Table 1). On the contrary, during the first 6-h 
orthostasis, ET-l urinary excretion increased and 
passed from 0.59 t 0.10 in supine position to 1.43 t 
0.28 pg/min (+142%, P < O.OOl)(Table 3). When ET-l 
urinary excretion was measured hourly, ET-1 renal 
formation was significantly increased from the first 
hour of orthostasis and gradually rose, plateauing after 
3 h and reaching a value twofold higher than baseline 
(from 0.59 2 0.19 to 1.52 t 0.31 pg/min, an increase of 
+158%, P < O.OOOl)(Fig. 1, Table 2) without any 
further significant hour-to-hour variations (P < 0.001 
vs. supine by ANOVA test). Analysis of the reverse- 
phase HPLC profile of ET-l immunoreactivity in urine 
samples pooled during the fourth and fifth hour after 
the assumption of the standing position did not show 
any significant changes in comparison with baseline 
(Fig. 2). During the period of standing position, total 
urinary volume and sodium excretion significantly 
decreased (Table 3). 
Orthostasis was associated with important changes 
in plasma renin activity and renal functions (Table 3). 
Plasma renin activity rose from 0.64 t 0.19 to 1.72 t: 
0.48 and 2.31 _ + 0.74 ng ANG Ih-l l ml-l (P < 0.003) 
after 1 and 2 h, respectively, and remained elevated for 
the entire observation period (2.29 t 0.57 ng ANG 
Ihl~rnl-l after 6 h, P < 0.002, and 1.7 2 0.31 ngANG 
1-h-l *ml-l after 12 h, P < 0.01). Free water reabsorp- 
tion and lithium clearance were significantly reduced 
during orthostasis (Table 3). GFR as expressed by 
creatine clearance slightly, but not significantly, de- 
creased (Table 3). 
Free water reabsorption as a fraction of GFR 
(THzo/GFR) was unaffected by orthostasis [not signifi- 
cant (NS)](Table 3). Urinary flow rate measured hourly 
significantly decreased from the first hour of orthosta- 
sis, from 0.99 t 0.18 at baseline to 0.60 t 0.15 (P < 
0.005) and 0.44 t 0.10 ml/min (P < 0.0005 vs. baseline) 
after 1 and 2 h standing, respectively (Table 4). No 
further significant hour-to-hour variation was found 
during the succeeding 4 h of observation (P < 0.001 vs. 
supine by ANOVA test)(Table 4, Fig. 1). Urinary flow as 
a fraction of GFR (V/GFR) was significantly reduced 
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Table 2. ET-l hourly urinary excretion and percent changes vs. baseline during three experimental periods 
Hours 
Supine 
Hourly urinary 
excretion, pg/min %Change 
Standing 
Hourly urinary 
excretion, pg/min %Change 
Standing-Supine 
Hourly urinary 
excretion, pg/min %Change 
8 0.63+0.15 
9 0.57 -+ 0.11 
10 0.57+0.13 
11 0.54kO.16 
12 0.65t0.13 
13 0.62 to.07 
14 0.58kO.09 
15 0.63kO.10 
16 0.6EO.12 
17 0.57 t 0.09 
18 0.64kO.11 
19 0.66+0.10 
20 0.66+0.13 
-10 
-10 
-14 
3 
-1 
-8 
0 
-3 
-10 
1 
5 
4 
0.59 + 0.19 
1.10 2 0.30 
1.31% 0.35 
1.52 t 0.31 
1.59 + 0.31 
1.50 ” 0.31 
1.58 + 0.29 
1.57 + 0.35 
1.61 -t- 0.27 
1.61% 0.22 
1.58 + 0.27 
1.57 + 0.36 
1.53 + 0.35 
86*$ 
123"f+ 
158.N 
169-f-§ 
154-N 
167"rrj 
1W§ 
1731-s 
173tg 
167"f$ 
~w-$ 
160-f-z 
0.58kO.11 
1.09-+0.26 
1.29t0.23 
1.45 kO.16 
1.45 kO.20 
1.43 20.18 
1.43 kO.26 
0.91+0.09 
0.74kO.17 
0.65-t-0.16 
0.6OkO.16 
0.63kO.20 
0.66+0.16 
87*$ 
lW§ 
lw-8 
15o”rcj 
147”r$ 
14wi 
56*$ 
28 
13 
4 
8 
13 
Values are means -t SD. “:P -=c 0.05; tP < 0.001 vs. baseline (8 AM). $P < 0.05; §P < 0.001 vs. supine position. 
during standing (P < O.O03)(Table 3). After the stand- 
ing position was assumed, the relationship of 
T,+/GFR as a function of urinary flow linearized 
(Fig. 3). 
When the subjects returned to the supine position 
after 6 h of orthostasis, plasma ET-l did not signifi- 
cantly change, whereas urinary ET-l excretion promptly 
decreased, and after 2 h it was no longer different from 
that observed at the same time during the 12-h supine 
period (Table 2, Fig. 1). Urinary flow rate increased 
from 0.60 t 0.21 to 0.81 ? 0.28 ml/min after 1 h (P < 
0.05 vs. orthostasis) and to 0.94 2 0.14 ml/min after 2 h 
(P < O.Ol)(Table 4). During the remaining period in the 
supine position no significant differences were found in 
comparison with the values observed during the 12-h 
period in the supine position (Table 4, Fig. 1). 
03 
0 2 4 6 8 10 12 
Time (h) 
0 2 4 6 8 IO 12 
Time (h) 
Fig. 1. Hourly urinary endothelin-1 (ET-l) excretion and urinary 
volumes during 12 h of supine position (O), 12 h of upright position 
(O), and 6 h of orthostasis followed by 6 h of supine position (0) in 
healthy subjects (n = 7). *P < 0.05 vs. supine position. 
Relationship Between ET-l Formation and RAS 
Ramipril administration to subjects in supine posi- 
tion caused the expected inhibitory effects on RAS. 
Plasma renin activity increased from 0.78 t 0.28 to 
1.12 2 0.38 ngANG Ih-l l ml-l (P < 0.01). Inhibition of 
RAS in the supine position did not change ET-l concen- 
tration in plasma or ET-l urinary excretion in compari- 
son with placebo. On the contrary, the 6-h urinary flow 
and sodium excretion rates significantly increased to 
1.94 t 0.64 ml./min (+48%, P < 0.05) and 0.24 t 0.04 
meq/min (+33%, P < O.OS), respectively. Creatine clear- 
ance slightly but nonsignificantly decreased (106 t 25 
ml/min, -14%; NS). Lithium clearance and free water 
reabsorption increased on average -48 and -59% (P < 
0.02 and P < 0.03, respectively)(Table 3). Tu,o/GFR and 
V/GFR were both significantly increased (P < 0.01 and 
P < 0.02, respectively) in comparison with the supine 
position after placebo. Ramipril did not alter the rela- 
tionship between Tn&GFR and V/GFR in the supine . , . 
position. 
The increase in ET-l urinary excretion induced by 
orthostasis was attenuated but not eliminated by 
ramipril administration. In fact, the mean ET-l uri- 
nary excretion, which was 1.43 IT 0.28 pg/min during 
orthostasis with placebo, decreased to 1.04 t 0.20 
pg/min during orthostasis with ramipril (P < O.Ol), 
with a mean increase of 100% over ET-l excreted 
during the 6-h supine position after ramipril adminis- 
tration (0.52 t 0.18 pg/min, P < O.OOZ)(Table 3). Also, 
the changes in renal function induced by orthostasis 
were attenuated but not eliminated by the administra- 
tion of ramipril (Table 3, Fig. 3). More precisely, urinary 
flow and sodium excretion rates decreased to 0.62 t 
0.21 ml/min (-68%, P < 0.05) and 0.16 t 0.06 meq/min 
(-33%, P < 0.05), respectively. GFR did not signifi- 
cantly change (101 t 12 ml/min, -5%; NS), whereas 
lithium clearance and free water reabsorption de- 
creased to 21 t 3 ml/min (-44%, P < 0.02) and 1.05 t 
0.17 ml/min (-46%, P < 0.05), respectively (Table 3). 
Tn&GFR significantly decreased (P < 0.01) and V/GFR 
similarly decreased (P < O.O07)(Table 3). The slope of 
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Table 3. Renal response to 6-h standing after placebo and ramipril(5 mg) administration 
Supine 
Placebo 
Standing %Difference Supine 
Ramipril 
Standing %Difference 
ET-l excretion rate, pg/min 
V, mllmin 
I&, meq/min 
GFR, ml/min 
CT,i, ml/min 
C osm, mllmin 
CH,~, ml/min 
TH,o, ml/min 
Tn,o/lOO ml GFR, ml/min 
V/l00 ml GFR, ml/min 
0.59 t 0.10 
1.31+ 0.50 
0.18 + 0.06 
123 2 25 
2555 
2.5420.64 
- 1.2 + 0.3 
1.22 + 0.32 
1.00 + 0.28 
1.112 0.56 
1.43 + 0.28”r 142 
0.50 k 0.27* -62 
0.08 + 0.03* -55 
102 k 21 -17 
15-+5t -39 
1.44 + 0.60* -43 
-0.9 + 0.3:‘: 24 
0.93 + 0.32:” -24 
0.96 2 0.43 -4 
0.52 2 0.34”’ -53 
0.52 + 0.18 
1.94 + 0.64$ 
0.24 t 0.04$ 
106 + 25 
37 + 12$ 
3.89 + 0.94# 
- 1.9 ‘- 0.8$ 
1.94 2 0.82$ 
1.85 + 0.52$ 
1.83 2 1.04$ 
1.04 k 0.20*$ 100 
0.62 -+ 0.21*: -68 
0.16 + 0.06*$ -33 
101 t- 12 -5 
21-+ 3*+ -44 
1.67 + 0.34*‘$ -57 
-1.12 0.2y 46 
1.05 + 0.17:‘:$ -46 
1.05 + 0.20”’ -43 
0.63 -+ 0.28* -65 
Values are means + SD. V, urinary volume flow rate; U Na, urinary sodium excretion; GFR, glomerular filtration rate; CI,i, lithium clearance; 
C Oslll, osmolar clearance; Cn,O, free water clearance; Tn,o, free water reabsorption. *P < 0.05; tP < 0.001 standing vs. supine. $P < 0.05 
ramipril day vs. placebo day. 
this relationship differed between placebo and ramipril 
(Fig. 3). 
Thus the inhibition of RAS did not eliminate either 
the increase of ET-l excretion or the changes of renal 
function induced by orthostasis. 
DISCUSSION 
The present results indicate that urinary ET-1 excre- 
tion significantly increases when the subjects assume 
the standing position, whereas ET-1 plasma concentra- 
tion substantially does not change. An important corol- 
lary arising from this completely different pattern is 
new evidence that plasma and urinary ET-1 are the 
expression of two different functional systems (22). 
The very short-lasting increase in ET-1 plasma con- 
centration after orthostasis agrees with a previous 
observation (29) of a rapid but unsustained increase in 
plasma ET-l concentration after 5 min of upright 
tilting. The absence of any significant increase in ET-1 
plasma concentration during prolonged standing, as in 
the present study, indicates that ET-1 arising from 
vascular endothelial cells plays a minor role in the 
occurrence of the complex cardiovascular adjustments 
to postural changes. However, a definite conclusion 
cannot be drawn, because ET-l may work in a para- 
crine way and its variations in plasma concentration 
might not be adequate to demonstrate the formation 
and release of ET-l (8). 
Renal ET-1 seems to be involved in the prolonged 
response to postural changes. The assumption of up- 
right position was associated with a marked increase in 
the excretion of urinary ET-l, which remained high 
throughout the duration of standing. When the subjects 
returned to the supine position, ET-l urinary excretion 
returned to baseline values. 
The increased urinary ET-1 excretion independent of 
the ET-1 plasma concentration supports a renal source 
of urinary ET-l. A growing body of evidence has shown 
that both cortex and renal medulla are important sites 
of ET-1 synthesis (25). Immunoreactive ET-l-like mate- 
rial and preproendothelin-1 mRNA have been found in 
human renal medulla, in capillary network cells of vasa 
recta, and in medullary collecting ducts (15,23,24). 
The modifications of ET-1 urinary excretion related 
to postural changes were consistent with those of 
plasma renin activity, and when the RAS was inhibited 
by ramipril administration the ET-l urinary excretion 
significantly lowered, indicating that the RAS operates 
an important control on the renal ET-1 formation. Thus 
this finding seems to confirm in humans the observa- 
tion that ANG II stimulates ET-1 formation (6, 17, 38) 
in cultured endothelial and mesangial cells. 
The control of RAS on ET-l renal formation was more 
evident when the RAS was activated, as occurs during 
orthostasis, because the inhibition of RAS in the supine 
position caused only a slight, nonsignificant (-12%) 
Fig. 2. Reverse-phase high-performance liquid chromatog- 
raphy profile of ET-l immunoreactivity in human urinary 
@ 
extracts before and after 4-5 h of upright position. Filled 
lss 30 
3 n, 
columns indicate concentrations of ET-l immunoreactivity 
in each fraction. Arrows, elution position of standard ET-l. 
:g 20 
Solid line, a linear gradient of acetonitrile from 30 to 60%. 
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Table 4. Hourly urinary flow rate (v) and percent 
changes vs. baseline during three experimental periods 
Supine Standing Standing-Supine 
v, Y Y 
Hours ml/min ?&Change ml/min %Change ml/min Whange 
8 0.93kO.14 
9 0.96kO.21 
10 0.96t0.17 
11 0.96t0.16 
12 0.99kO.20 
13 1.01~ 0.16 
14 1.02 -+ 0.12 
15 1.01+0.18 
16 l.OO+O.ll 
17 0.91-+0.17 
18 0.99 -t 0.18 
19 1.01+0.18 
20 1.03 kO.21 
0.99kO.18 0.91+0.07 
3 0.6OkO.15 -39:':$ 0.6lkO.16 -33*$ 
3 0.441kO.10 -5675 0.44kO.15 -52-1-g 
3 0.45kO.11 -55-r3 0.40t0.12 -56f$ 
6 0.4920.15 -51-j-g 0.4220.13 -5419 
9 0.47kO.13 -53~5 0.47-tO.19 -48:R$ 
10 0.48kO.14 -52"'s 0.6OkO.21 -34'k+ 
9 0.49 to.15 -51-1-s 0.8lk 0.28 -11 
8 0.57t0.17 -42-i-s 0.94kO.14 3 
-2 0.6lkO.20 -38$'$ 1.00~0.27 10 
6 0.54t0.17 -45"r23 0.9820.26 8 
9 0.5EO.16 -48-;-s 1.02kO.22 12 
11 0.57 kO.19 -42'i'$ 1.08 20.24 19 
Values are means + SD. :“P < 0.05; TP < 0.001 vs. baseline (8 AM). 
$P < 0.05; §P < 0.001 vs. supine position. 
reduction in ET-1 urinary excretion, whereas the inhibi- 
tion of RAS during orthostasis was associated with a 
significant reduction (-27%) in ET-l urinary excretion. 
However, it is important to stress that the ET-l urinary 
excretion markedly increased during standing (+ lOO%), 
even in the presence of RAS inhibition. Thus the 
involvement of ET-1 in the postural changes parallels 
but is largely independent of the RAS activation. 
Changes in renal functions following standing are 
characterized by reduction in creatinine and lithium 
clearances and by the contraction of urinary volume 
and sodium excretion associated with an increased free 
water clearance. These functional changes agree with 
the well-known changes in plasma volume following 
E 2.0 - 1 
Jk 1.5- 
z cJ l.O- -E 
F 0.5 - 
,” O-- I” 
A 2.0- 
1.5- 
0 
O”o 0 0 I-O- 
0 0.5- 0.97 
1 I I I 01 
0.5 1.0 1.5 2.0 0.5 1.0 1.5 2.0 
WOO ml GFR (ml/min) V/100 ml GFR (ml/min) 
l 
e 
2.0- 
1.5- 
1 .o- 
0.5- 
I  I  I  ” . I  ” 0-I 
0.5 1.0 1.5 2.0 
V/100 ml GFR (ml/min) 
/ 
f 0 
l 
r = 0.80 
slope = 0.56 
0.5 I’.0 I’.5 i.0 
V/l 00 ml GFR (ml/min) 
Fig. 3. Free water reabsorption (T vzo) plotted as a function of distal 
delivery of filtrate, estimated by urine flow rate (V), using data from 
placebo (0) and ramipril day (a) in supine (A) and erect posture (B). 
Tn,o and V are factored by glomerular filtration rate (GFR, creatinine 
clearance) to correct for small variations in filtration rate. 
the standing position (7, 19>, considered as a conse- 
quence of the redistribution of blood to the arms and 
legs (32) and renal blood flow decrease (1, 32). The 
inhibition of RAS by ramipril administration did not 
cancel these changes but reset them to a lower level. 
The evident changes in renal function following the 
assumption of standing position were associated with a 
marked increase of urinary ET-1 excretion (+lOO%), 
suggesting a participation of renal ET-1 in renal func- 
tional adaptation to postural changes independently of 
the activity of RAS. In this context, the effects of renal 
ET-1 on renal functions are quite similar to (3) but 
largely independent of those of RAS (2). 
The present results do not allow insight into the 
mechanism(s) responsible for the increased ET-1 renal 
formation. ET-1 concentration in renal venous blood 
was not measured, so we are unable to determine 
whether orthostasis, by reducing renal blood flow (1), 
may stimulate ET-1 formation by vascular endothe- 
lium. Upright posture has been reported to stimulate 
arginine vasopressin peptide (AVP)( 1,lZ). The redistri- 
bution of relationship between free water reabsorption 
and urinary flow rate induced by orthostasis suggests a 
release ofAVP (31). The reduced slope of the plot during 
orthostasis after ramipril may suggest a reduced AVP 
activity consequent to RAS inhibition (2). Specifically 
designed investigations are needed to clarify this issue. 
Moreover, the present results are not able to establish 
whether renal ET-1 is responsible for the renal func- 
tional adaptations to orthostasis because these might 
be consequent to both the modifications in baroreceptor 
activity and neurohormonal changes related to pos- 
tural changes (1). Only by the use of specific ET-1 
antagonists can this problem be clarified. 
In conclusion, the present findings indicate both that 
renal ET-l excretion is augmented in the standing 
position and that ET-1 renal formation is partially 
controlled by RAS. The renal functional adaptations to 
postural changes remain very clear even after RAS 
inhibition and are associated with a consistent increase 
in renal ET-l. 
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